Heart failure & cardiomyopathies

Effect of Acoramidis on Heart Failure–Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial

JAMA CardiolPublished Secondary analysis of the ATTRibute-CM randomised trial

Primary result · KCCQ-OSResult — go to the resultLSM difference 9.9 95% CI 6.0–13.9

Authors' conclusion

In this secondary analysis of the ATTRibute-CM randomized clinical trial, in patients with ATTR-CM, acoramidis significantly attenuated the decline in HF-related health status compared with placebo.

Study context

Population
Adults with transthyretin amyloid cardiomyopathy (ATTR-CM)611 in modified ITT
Participants
632 adults
Comparison
Acoramidis vs placebo
  • Acoramidisn = 409
  • Placebon = 202reference
Primary endpoint
LSM difference in KCCQ-OS (prespecified secondary outcome of the trial)
Follow-up
Over 30 months
Methodological detailsphase 3, multicentre, international, placebo-controlled
  • Phase 3
  • Multicentre
  • International
  • Placebo-controlled

Primary result

KCCQ-OS · month 30

Least-squares mean (LSM) difference

9.9

95% CI 6.0–13.9

P < 0.001

Acoramidis vs Placebo
LSM difference 9.9 (95% CI 6.0–13.9); P < 0.001

As reported in the abstract

Secondary outcomes

OutcomeAcoramidisPlaceboOR (95% CI)P value
Alive and not worse (KCCQ-OS <5-point decrease; post hoc) · month 30 · NNT = 6 · post hoc47%30%2.1 (1.4–3.1)P < 0.001
Alive and well (KCCQ-OS >60 and <10-point decrease; post hoc) · month 30 · NNT = 7 · post hoc46%31%1.9 (1.3–2.8)P < 0.001
Alive and better (KCCQ-OS >5-point increase; post hoc) · month 30 · NNT = 9 · post hoc25%14%2.1 (1.3–3.4)P = 0.002
  • Alive and not worse (KCCQ-OS <5-point decrease; post hoc): at month 30: acoramidis 367, placebo 188

Original publication

Effect of Acoramidis on Heart Failure–Related Health Status: A Secondary Analysis of the ATTRibute-CM Randomized Clinical Trial. JAMA Cardiol. Published 1 September 2026. doi:10.1001/jamacardio.2026.2413

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.